After Frequency Therapeutics (FREQ) disclosed that the company’s Phase 2b study assessing small molecule FX-322 in acquired sensorineural hearing loss, or SNHL, did not achieve its primary endpoints, H.C. Wainwright analyst Joseph Pantginis said the study failure highlights Decibel Therapeutics’ (DBTX) differentiated therapeutic approach with its own gene therapy strategies. Though it is still in early stages of development, Decibel has its own SNHL program, said the firm, which believes Frequency’s unsuccessful trial and hearing loss program discontinuation represents an opportunity for Decibel. H.C. Wainwright has a Buy rating and $23 price target on Decibel shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
- 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $11 (or More)
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
- Decibel Therapeutics announces approval of CTA by U.K. MHRA for DB-OTO